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Abstract
Background—Meningococcal disease incidence in the U.S. is at an all-time low. In a previous 
study of Georgia high school students, meningococcal carriage prevalence was 7%. The purpose 
of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y 
meningococcal carriage and to define the dynamics of carriage in high school students.
Methods—This was a prospective cohort study at 8 high schools, 4 each in Maryland and 
Georgia during a school year. In each state, 2 high schools were randomized for participating 
students to receive MCV4-DT at the beginning of the study and 2 at the end. Oropharyngeal swab 
cultures for meningococcal carriage were performed three times during the school year.
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Results—Among 3,311 students, prevalence of meningococcal carriage was 3.21%–4.01%. 
Phenotypically non-groupable strains accounted for 88% of carriage isolates. There were only 5 
observed acquisitions of serogroup Y strains during the study; therefore, the impact of MCV4-DT 
on meningococcal carriage could not be determined.
Conclusions—Meningococcal carriage rates in U.S. high school students were lower than 
expected and the vast majority of strains did not express capsule. These findings may help explain 
the historically low incidence of meningococcal disease in the U.S.
Background
Adolescents are at increased risk for infection with Neisseria meningitidis, an important 
cause of serious invasive disease including meningitis and septicemia in the U.S. (1). Since 
2005, the Advisory Committee on Immunization Practices has recommended quadrivalent 
meningococcal conjugate vaccine that covers serogroups A, C, W, and Y (MCV4) for all 
adolescents (2,3).
Nasopharyngeal carriage of N. meningitidis, a prerequisite for the development of invasive 
meningococcal disease, is in most cases asymptomatic and results in strain-specific 
immunity (4). Meningococcal carriage rates are variable by age, with adolescents and young 
adults having the highest prevalence (5–14). Because of high rates of carriage and evidence 
for transmission within families, adolescents are considered to be a primary reservoir for 
transmission to other groups including young children and infants (15).
Polysaccharide-protein conjugate vaccines against Haemophilus influenzae type b and 
Streptococcus pneumoniae prevent acquisition of carriage, which interrupts transmission and 
leads to protection of unvaccinated persons (16,17). With the implementation of a national 
serogroup C vaccination program in the U.K., substantial reductions in serogroup C 
meningococcal carriage and disease were observed in vaccinated persons, with similar 
declines in both carriage and disease occurring in the unvaccinated (5,18–20). Similarly, 
early results from the African meningitis belt suggest that the recently-introduced serogroup 
A conjugate vaccine has led to interruption of transmission of serogroup A meningococcal 
carriage (21). Such herd protection can dramatically enhance the public health benefits of 
conjugate vaccination programs. As a result, the ability of conjugate vaccines to prevent 
meningococcal carriage has become an important post-licensure evaluation question.
The main purpose of this study was to assess the impact of MCV4 on serogroup Y 
meningococcal carriage among Georgia and Maryland high school students. Serogroup Y 
was chosen because it caused approximately one-third of meningococcal disease reported in 
the U.S. from 1996–2007, and was the most frequently isolated serogroup in a previous 
carriage study among Georgia high school students (22). We also sought to study the 
dynamics of carriage in this population. At the time of the study, the incidence of invasive 
meningococcal disease in the U.S. was falling to historically low levels (1). During 2006–
2007, MCV4 coverage rates among children 13–17 years old were estimated to be 11%–
32% (23,24).
Harrison et al. Page 2
J Infect Dis. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods
Study design
This study was approved by the institutional review boards of the CDC, Maryland 
Department of Health and Mental Hygiene, Johns Hopkins Bloomberg School of Public 
Health, and Georgia Department of Human Resources. Written informed consent was 
obtained for all participating students. For students <18 years old, consent was also obtained 
from the parent or guardian as well as student assent. Students were paid $10 for full 
participation at each survey. Full participation at each survey included a pharyngeal swab 
and completion of a study questionnaire. MCV4 was offered to consenting non-vaccinated 
study participants either at the initial survey or at the final survey depending on the school’s 
randomization.
The study design was a field trial comprising three sequential, cross-sectional pharyngeal 
carriage surveys spanning the 2006–2007 school year (clinical trials registration 
NCT00119080). Eight public high schools were included: four in Baltimore County, 
Maryland and four in Douglas County, Georgia. Two schools at each site were randomized 
for their participating students to be offered free immunization at the time of initial carriage 
survey toward the beginning of the school year (vaccination schools), while participants at 
the other two schools at each site were offered free immunization at the third survey toward 
the end of the school year (control schools). The baseline carriage survey and school-based 
vaccination clinic for vaccination schools, were completed at the same visit within 1 to 2 
months of the start of the school year, with subsequent surveys completed at approximately 
3 and 6 to 7 months later.
A questionnaire was also completed at the time of each survey to identify potential risk 
factors for meningococcal carriage including demographic and household variables, recent 
illness, smoking and antibiotic use.
In a previous meningococcal carriage study among Georgia high school students, the 
prevalence of serogroup Y carriage was 2.5%–3.5% (22). Therefore, for the present study, 
we estimated a baseline prevalence of serogroup Y carriage of 2%. To detect a 50% 
reduction in serogroup Y carriage, we estimated that approximately 2,000 study subjects in 
each group would be required from vaccination and control schools at each round.
Data and specimen collection
Oropharyngeal swab specimens were collected from participating students by trained study 
workers who swabbed both tonsillar pillars and the oropharynx. Swabs were inoculated and 
streaked for incubation by trained laboratory personnel directly onto culture plates 
containing Thayer Martin Improved medium (R01886; Remel, Inc., Lenexa, KS) at each 
high school and placed in Mitsubishi boxes to generate a CO2-enriched atmosphere during 
holding and transport. During and at the end of each survey session, culture plates were 
transported to participating laboratories for incubation and primary identification. To ensure 
that N. meningitidis was not lost in transport, a control plate was inoculated each day with 
N. meningitidis and transported with the study plates before incubation; good growth was 
noted on all control plates.
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MCV4 immunization
Students in vaccination schools received a single intramuscular dose of A, C, W, Y 
meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-
DT) (Menactra, Sanofi Pasteur), the only licensed MCV4 at the time, during the first survey. 
Students in control schools were offered vaccination at the third survey.
Laboratory methods
Species and phenotypic serogroup identification for serogroups A, B, C, E, W, X, Y, Z (8 of 
12 meningococcal serogroups) were performed using standard biochemical tests and slide 
agglutination, respectively. To determine the genotypic capsular group, serogroup-specific 
(SGS)-PCR was performed using an assay that determines the genetic capsular type for the 
six serogroups that cause invasive meningococcal disease: A, B, C, W, X, and Y (25). An 
isolate was defined as nongroupable for the phenotypic or genotypic assays when it did not 
react in either the phenotypic or SGS-PCR assays, respectively. Genotypic capsular group 
was determined independently of phenotypic serogroup. Further isolate characterization was 
performed using multi-locus sequence typing (MLST), and porA, porB, and fetA genotyping 
(outer membrane protein genotyping) as previously described (26).
Data analysis
Analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). The impact of 
vaccination on both prevalent and incident carriage of serogroup Y meningococcus was 
evaluated. We compared the proportion of students carrying serogroup Y in vaccination 
schools to the proportion carrying serogroup Y in control schools in each swab survey using 
Fisher’s exact test. We also compared the rate of acquisition of serogroup Y carriage among 
students in vaccination and control schools. Rates of acquisition were measured as new 
carriers of serogroup Y meningococcus identified in rounds two and three per 1,000 students 
who had participated in more than one round. Rate ratios were calculated for serogroup Y 
carriage at vaccination versus control schools at the time of each survey.
For the purpose of further defining the dynamics of carriage in this population, we assessed 
strain evolution and carriage with different strains among students with carriage on at least 
two surveys. Strain evolution was defined as carriage of an isolate of the same clonal 
complex (CC) but a different sequence type and/or change in the outer membrane protein 
genotype. Strain replacement was defined as carriage of an isolate of a different CC. 
Genotyping was repeated on isolates to confirm suspected strain evolution.
Risk factors for carriage were evaluated by comparing questionnaire answers from students 
who were carriers and those who were non-carriers. Risk factors were first assessed using 
stratified univariate logistic regression using school as the stratification variable to adjust for 
clustering within schools on demographic, household and symptom variables. Factors with a 
p-value less than 0.2 in the univariate analysis were eligible for entry into a stratified 
multivariable stepwise logistic regression model. Factors that remained significant in the 
multivariable model were checked for interactions.
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Results
In total, 3,311 students were enrolled. In the first survey round, 1,731 students were included 
from the four vaccination schools and 1,543 from the control schools. In Georgia, there were 
13 students at control schools and 24 at vaccination schools who did not participate in the 
first survey but did participate in the second. From the first to the third survey, loss to 
follow-up was 12.7%, with 11.7% loss in vaccination schools and 13.8% in control schools. 
In Georgia, study participation by school among eligible students ranged from 23%–31% 
and in Maryland participation was 20%–27%.
The median age of participants was 16 years, with comparable representation achieved 
among the four school grades. Of all participants, 45.2% were male, 61.6% were white, and 
7.2% were Hispanic. Demographic characteristics were generally comparable between 
students in vaccination and control schools, although students in control schools were more 
likely to be white and smokers and to have less paternal education (Table 1).
Prevalence of carriage and serogroup distribution
In the first survey, the prevalence of meningococcal carriage was 3.21%, with 3.52% in 
vaccination schools and 2.85% in control schools (p=0.32) (Table 2). For that survey, 
carriage prevalence in Maryland was 3.91% compared to 2.68% in Georgia (p=0.06). In 
Maryland and overall, carriage prevalence trended upward in both vaccination and control 
schools over the course of the school year. This was largely driven by phenotypic non-
groupable meningococcal carriage. A similar trend was not observed in Georgia. By the final 
survey, overall carriage prevalence in Maryland was 5.91% vs. 2.63% in Georgia (p 
<0.0001).
In total, 325 meningococcal isolates were identified during all 3 survey rounds: 138 from 
Georgia and 187 from Maryland students. Of these, 285 (88%) were non-serogroupable, 26 
(8%) were serogroup Y, and 14 (4%) were serogroup B. No serogroup C isolates were 
identified. Serogroup Y was more common in Maryland than in Georgia, while serogroup B 
was not encountered in Maryland (Table 2). Among the 285 non-serogroupable isolates, 60 
(21%), 5 (2%), and 39 (14%) were genotypic capsular groups B, C, and Y, respectively. 
Based on the combination of both phenotypic and genotypic typing of the 325 isolates, 20% 
were group Y, 23% were group B and 1.5% were group C.
Impact of MCV4-DT on prevalent and incident serogroup Y carriage
The proportions of students with carriage of serogroup Y strains at baseline in the 
vaccination and control schools were 0.35% and 0.19%, respectively (p=0.51) (Table 2). 
Over the course of the three survey rounds, the prevalence of serogroup Y carriage did not 
change substantially in either group. Only 5 acquisitions of serogroup Y carriage were 
observed, 3 (1.79 per 1000 students) in the vaccination schools and 2 (1.34 per 1000 
students) in the control schools (rate ratio 1.34, 95% confidence interval 0.18 to 11.39). In 
an analysis of genotypic group Y carriage, 10 students (5.97 per 1000 students) in the 
vaccinated schools and 10 students (6.69 per 1000 students) in the control schools acquired 
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genotypic group Y carriage over the course of the three survey rounds (rate ratio 0.89, 95% 
confidence interval 0.34 to 2.31).
Risk factors for meningococcal carriage
On univariate analysis adjusted for clustering by school, risk factors for carriage were white 
race, being in grades 11 or 12, older age, being a current smoker, and living in a household 
with other smokers (Table 3); gender, Hispanic ethnicity, housing type; parental education, 
symptoms in the past two weeks, antibiotic use in the past 30 days, and household crowding 
were not associated with carriage (data not shown). Meningococcal carriage was observed 
during at least one survey round in 8.0% of white students versus vs. 2.1% of non-white 
students (p<0.0001), 8.0% of students in grades 11 or 12 versus 3.4% in grades 9 or 10 
(p<0.0001), 12.1% for current smokers versus 5.0% for non-smokers (p<0.0001), and 7.4% 
for students who lived in a household with other smokers versus 4.6% of those who did not 
(p=0.012).
In multivariable logistic regression analysis adjusted for clustering, factors independently 
associated with carriage were white race (odds ratio 3.2, 95% CI 2.1–4.9), being a current 
smoker (OR 1.6, 1.1–2.4), and older age (OR 1.3, 1.2–1.5).
Duration of carriage
Among 2,799 students who participated in all three survey rounds, 163 (5.8%) were positive 
during at least one survey. Of these, 36 (22.1%) were positive for carriage at all three 
surveys (approximately 6 months or more of continuous carriage), 11 (6.8%) at survey 1 and 
3, 13 (8.0%) at surveys 1 and 2 (2–3 months), 23 (14.1%) at surveys 2 and 3 (3–5 months), 
and 25 (15.3%), 11 (6.8%), 44 (27.0%) at surveys 1,2, or 3 only, respectively (total 49.1% 
positive at only one survey). Among those who were positive for carriage on at least one 
survey, there was no statistically significant difference in the frequency of positive carriage 
isolates by race, age, Hispanic ethnicity, high school grade, gender, whether the strain was 
encapsulated, or phenotypic or genotypic serogroup (data not shown).
Molecular characterization of carriage isolates
Among 325 carriage isolates from 189 students, 76 sequence types (STs) representing 18 
CCs were identified (Figure 1 and Supplemental Table 1) ; 20 isolates could not be assigned 
to a CC. Thirteen STs comprised more than 5 isolates each, and represented 64% of all 
isolates recovered. Thirty-five STs were represented by only one isolate each. Among CCs 
with more than 10 isolates, the most common CCs and the serogroup that is often associated 
with each CC (pubmlst.org/neisseria), were ST-198, non-groupable capsule null locus (cnl) 
locus (73 isolates); ST-23 (61 isolates), serogroup Y; ST-41/44 (40 isolates), serogroup B; 
ST-60 (33 isolates), serogroup E; ST-1157 (21 isolates), encapsulated but non-groupable; 
ST-35 (19 isolates), serogroup B; and ST-53 (10 isolates), non-groupable cnl (Figure 1). 
Among 98 students who had carriage on at least two occasions, strain evolution was 
observed in 5 students: 3 had a change in the porA allele, and 1 each had a change in the 
porB or fetA allele (Table 4). Two students were observed to have strain replacement.
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Discussion
The most remarkable finding of this study is that the prevalence of meningococcal carriage 
among Georgia and Maryland high school students was around 3%, which was much lower 
than expected based on previous studies. For example, in a study among Georgia high school 
students in 1998 using similar methodology, overall carriage rates were 6.1%–7.7% (22). 
Our observed carriage rate was also much lower than has been reported for U.K. and 
German high school students and U.K. university students (5,27–29).
Another striking finding is that the proportion of isolates that were phenotypically non-
groupable was 88%, higher than in previous studies, in which approximately 30% of U.S. 
and 60% of U.K isolates from high school students were phenotypically non-groupable 
(5,22). Thus, the little carriage that we found was caused mostly by commensal 
meningococci that were not expressing capsule and therefore unlikely to cause invasive 
disease. In addition, of the 7 CCs represented by more than 10 carriage isolates, only 
CC-41/44 and CC-23 were common causes of invasive disease in the U.S. during 2000–2005 
(26). A limitation of our study is that the phenotypic and SGS-PCR assays detected 8 and 6, 
respectively, of the 12 meningococcal serogroups and therefore some of the isolates that we 
classified as nongroupable may have belonged to serogroups that rarely cause invasive 
disease (30).
These findings may at least in part explain the incidence of invasive meningococcal disease 
in the U.S., which peaked in the mid-1990’s due in large part to the emergence of serogroup 
Y and which has now declined to historically low levels (1). The low prevalence of carriage 
of meningococci and phenotypic encapsulated meningococci observed in this study among 
high school students may underlie the dramatic declines in disease incidence, probably 
through the mechanisms of natural immunity and reduced meningococcal transmission in 
the U.S. Similar to other studies in high school students, we found that smoking was a risk 
factor for meningococcal carriage (6,29).
Commensurate with the overall low observed carriage prevalence and the decline in disease 
incidence, much less serogroup Y carriage was observed than the 2.5%–3.5% that we 
considered in our sample size calculations. Furthermore, few instances of phenotypic 
serogroup Y carriage acquisition were observed. In addition, our enrollment of 
approximately 3,300 students was lower than anticipated. Therefore, the study did not have 
sufficient statistical power to assess the impact of MCV4-DT on meningococcal carriage. 
This experience indicates a need for pilot studies to determine the required sample size 
before large-scale carriage studies are undertaken. Such a pilot study would likely have 
demonstrated that a larger study was needed to assess the impact of MCV4-DT on carriage.
A recent study of a quadrivalent meningococcal conjugate vaccine that uses mutant 
diphtheria toxin (CRM) as the conjugate protein demonstrated a 39% reduction in serogroup 
Y carriage 2–12 months after vaccination (31). However, given the different carrier proteins 
and differences in the immunogenicity of the two vaccines, those results cannot necessarily 
be extrapolated to MCV4-DT (32).
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Among students who were carriers, approximately 22% had carriage during all three survey 
rounds, 22% during two consecutive rounds, 49% at one round, and 7% were intermittently 
positive (positive at rounds 1 and 3). In addition, 4% and 2% of students with persistent 
carriage had strain evolution or clonal replacement, respectively. Changes in porA and fetA 
alleles have been previously described (33); in our study, we also found a different porB 
allele in one student. However, it is possible that changes in strains between survey rounds 
were due to sampling error rather than true differences. The lack of serogroup B carriage in 
Maryland was an unexpected finding, particularly since 10 (29%) of 35 invasive isolates 
from Maryland during 2006 and 2007 were caused by serogroup B strains (data not shown).
In summary, we found a low prevalence of meningococcal carriage among high school 
students in Georgia and Maryland in 2006–2007 and that a high proportion of carried strains 
were unencapsulated. This study underscores the utility of carriage studies for better 
understanding the epidemiology of invasive meningococcal disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the students who participated in this study and the school officials and nurses who assisted us. We also 
thank the Baltimore County (MD) and Douglas County (GA) Health Department nurses, the staff of the Maryland 
Department of Health and Mental Hygiene and Georgia Division of Public Health Microbiology Laboratories, 
David Blythe, Patricia Ryan, Angela Badcon, Kim Holmes, Tia Johnson, Carolyn Kreiner, Janice Langford, 
Amanda Palmer, Elisabeth Vaeth, Jessica Tuttle, Heena Joshi, Sandra Bulens, Meghan Weems, Beth Ward, Melissa 
Tobin-d’Angelo, Cherie Drenzek, Monica Farley, Wendy Baughman, Stepy Thomas, Suzanne Segler, LeAnn Clark, 
Bill Shea, Mahin Park, Marsha Ray, Elizabeth Franko, and Alpha Bryan for their assistance with the study. Finally, 
we thank Xin Wang for her thoughtful review of the manuscript.
Funding
This study was funded by a grant from Sanofi Pasteur to the CDC Foundation. The study sponsor had no role in the 
development of the study protocol, the study conduct, data analysis or preparation of the manuscript.
Literature cited
1. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, 
Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, 
Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. Changes in 
Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for 
prevention of meningococcal disease. Clin Infect Dis. 2010; 50:184–191. [PubMed: 20001736] 
2. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of 
the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2005; 54:1–21.
3. Prevention and control of meningococcal disease. MMWR Recomm Rep. 2013; 62:1–22.
4. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. 
Development of natural immunity. J Exp Med. 1969; 129:1327–1348. [PubMed: 4977281] 
5. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C 
conjugate polysaccharide vaccination. Lancet. 2002; 359:1829–1831. [PubMed: 12044380] 
6. MacLennan J, Kafatos G, Neal K, Andrews N, Cameron JC, Roberts R, Evans MR, Cann K, Baxter 
DN, Maiden MC, Stuart JM. Social behavior and meningococcal carriage in British teenagers. 
Emerg Infect Dis. 2006; 12:950–957. [PubMed: 16707051] 
Harrison et al. Page 8
J Infect Dis. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
7. Imrey PB, Jackson LA, Ludwinski PH, England AC 3rd, Fella GA, Fox BC, Isdale LB, Reeves MW, 
Wenger JD. Meningococcal carriage, alcohol consumption, and campus bar patronage in a 
serogroup C meningococcal disease outbreak. J Clin Microbiol. 1995; 33:3133–3137. [PubMed: 
8586688] 
8. Stuart JM, Cartwright KA, Robinson PM, Noah ND. Effect of smoking on meningococcal carriage. 
Lancet. 1989; 2:723–725. [PubMed: 2570968] 
9. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage 
of meningococci and Neisseria lactamica. Epidemiol Infect. 1987; 99:591–601. [PubMed: 3123263] 
10. Riordan T, Cartwright K, Andrews N, Stuart J, Burris A, Fox A, Borrow R, Douglas-Riley T, Gabb 
J, Miller A. Acquisition and carriage of meningococci in marine commando recruits. Epidemiol 
Infect. 1998; 121:495–505. [PubMed: 10030697] 
11. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for 
meningococcal disease in college students. JAMA. 2001; 286:688–693. [PubMed: 11495618] 
12. Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, Razeq J, Roche 
JC. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001; 286:694–699. 
[PubMed: 11495619] 
13. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college 
students. JAMA. 1999; 281:1906–1910. [PubMed: 10349894] 
14. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a 
systematic review and meta-analysis. Lancet Infect Dis. 2010; 10:853–861. [PubMed: 21075057] 
15. Greenfield S, Sheehe PR, Feldman HA. Meningococcal carriage in a population of “normal” 
families. J Infect Dis. 1971; 123:67–73. [PubMed: 5100979] 
16. O’Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, Reid R, Becenti J, Kvamme S, 
Whitney CG, Santosham M. Effect of pneumococcal conjugate vaccine on nasopharyngeal 
colonization among immunized and unimmunized children in a community-randomized trial. J 
Infect Dis. 2007; 196:1211–1220. [PubMed: 17955440] 
17. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine 
on carriage of Haemophilus influenzae type b. J Infect Dis. 1995; 171:93–98. [PubMed: 7798687] 
18. Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, 
Kroll JS, Neal KR, Ala’aldeen DA, Crook DW, Cann K, Harrison S, Cunningham R, Baxter D, 
Kaczmarski E, Maclennan J, Cameron JC, Stuart JM. Impact of meningococcal serogroup C 
conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008; 197:737–743. [PubMed: 
18271745] 
19. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C 
conjugate vaccine in teenagers and toddlers in England. Lancet. 2001; 357:195–196. [PubMed: 
11213098] 
20. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from 
meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003; 
326:365–366. [PubMed: 12586669] 
21. Kristiansen PA, Diomande F, Ba AK, Sanou I, Ouedraogo AS, Ouedraogo R, Sangare L, Kandolo 
D, Ake F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-
King M, Djingarey MH, Messonnier NE, Preziosi MP, Laforce FM, Caugant DA. Impact of the 
serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin 
Infect Dis. 2013; 56:354–363. [PubMed: 23087396] 
22. Kellerman SE, McCombs K, Ray M, Baughman W, Reeves MW, Popovic T, Rosenstein NE, Farley 
MM, Blake P, Stephens DS. Genotype-specific carriage of Neisseria meningitidis in Georgia 
counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis. 2002; 186:40–
48. [PubMed: 12089660] 
23. National vaccination coverage among adolescents aged 13-17 years–United States, 2006. MMWR 
Morb Mortal Wkly Rep. 2007; 56:885–888. [PubMed: 17728694] 
24. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. MMWR Morb 
Mortal Wkly Rep. 2008; 57:1100–1103. [PubMed: 18846032] 
25. Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, Mayer LW, Phelan 
M, Taylor TH Jr, Bernhardt SA, Rosenstein NE, Popovic T. Use of real-time PCR to resolve slide 
Harrison et al. Page 9
J Infect Dis. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 
2004; 42:320–328. [PubMed: 14715772] 
26. Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, Whitney AM, Stephens 
DS, Cohn AA, Messonnier NE, Mayer LW. Population structure and capsular switching of 
invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era–United 
States, 2000-2005. J Infect Dis. 2010; 201:1208–1224. [PubMed: 20199241] 
27. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, Slack RC, Madeley RJ, Ait-Tahar K, Job K, Wale MC, 
Ala’Aldeen DA. Changing carriage rate of Neisseria meningitidis among university students 
during the first week of term: cross sectional study. Bmj. 2000; 320:846–849. [PubMed: 
10731181] 
28. Ala’aldeen DA, Oldfield NJ, Bidmos FA, Abouseada NM, Ahmed NW, Turner DP, Neal KR, 
Bayliss CD. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis. 
2011; 17:1762–1763. [PubMed: 21888817] 
29. Oppermann H, Thriene B, Irmscher HM, Grafe L, Borrmann M, Bellstedt D, Kaynak S, 
Hellenbrand W, Vogel U. Meningococcal carriers in high school students and possible risk factors. 
Gesundheitswesen. 2006; 68:633–637. [PubMed: 17099824] 
30. Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman 
JT, Zollinger WD, Frasch CE, Stephens DS, Feavers I, Frosch M, Parkhill J, Vogel U, Quail MA, 
Bentley SD, Maiden MC. Description and nomenclature of Neisseria meningitidis capsule locus. 
Emerg Infect Dis. 2013; 19:566–573. [PubMed: 23628376] 
31. Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath PT, Lewis DJ, Pollard 
AJ, Turner DP, Bazaz R, Ganguli A, Havelock T, Neal KR, Okike IO, Morales-Aza B, Patel K, 
Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MC, Toneatto D, Wang H, McCarthy M, Dull 
PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B 
meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical 
trial. Lancet. 2014
32. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM. Phase III comparison 
of an investigational quadrivalent meningococcal conjugate vaccine with the licensed 
meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009; 49:e1–10. 
[PubMed: 19476428] 
33. Bidmos FA, Neal KR, Oldfield NJ, Turner DP, Ala’Aldeen DA, Bayliss CD. Persistence, 
replacement, and rapid clonal expansion of meningococcal carriage isolates in a 2008 university 
student cohort. J Clin Microbiol. 2011; 49:506–512. [PubMed: 21123536] 
Harrison et al. Page 10
J Infect Dis. Author manuscript; available in PMC 2018 January 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Frequency distribution of clonal complexes (CC’s) for 325 meningococcal carriage isolates. 
Numbers following the CC designation represent the number of isolates.
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